An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits

An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits

Summary: Glycemic and body weight control gained from GLP-1R agonists remains an unmet need for diabetes and obesity treatment, leading to the development of GLP-1R/GIPR co-agonists. An imbalance in GLP-1R/GIPR agonism may extensively maximize the glucose- and weight-lowering effects. Hence, we prep...

Full description

Bibliographic Details
Main Authors: Xuan Xia, Qianmeng Lin, Zhan Zhou, Yongheng Chen
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:iScience
Subjects:
Pharmacology
Physiology
Cellular physiology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004224005984

Internet

http://www.sciencedirect.com/science/article/pii/S2589004224005984

Similar Items